Objective
To assess the effects of proteasome inhibition on the development of burn-induced hypermetabolism.
Methods
Rats underwent 30–40% TBSA scald burn or sham injury. The proteasome inhibitor bortezomib (0.1 mg/kg) or vehicle (n=10) was administered i.p. 3×weekly starting at 2h (Early-Bortezomib, n=20) or 48h (Late-Bortezomib, n=13) post-burn. Body weights were determined weekly. Resting energy expenditures (REE) were measured at days 0 (baseline), 7, 14, 21 and 42 post-burn. At day 42, blood and pectoral muscle were harvested. Routine blood chemistry parameters were analyzed. Proteasome content, proteasome peptidase activities and ubiquitin-protein conjugates were measured in muscle extracts.
Results
As compared with sham-vehicle treated animals, specific proteasome activities were increased after burn and vehicle treatment. Bortezomib treatment inhibited proteasome activities and increased ubiquitin-protein conjugates after sham and burn injury. Bortezomib treatment did not affect REE after sham procedure. REE significantly increased by 47% within 7 days and remained elevated until day 42 after burn and vehicle treatment. After Early-Bortezomib treatment, burn-induced increases in REE were delayed and significantly reduced by 42% at day 42, as compared with vehicle treatment. With Late-Bortezomib treatment, burn-induced increases in REE were also delayed but not attenuated at day 42. Mortality was 20% with vehicle, 65% (median survival time: 1.875 days) with Early-Bortezomib and 25% with Late-Bortezomib treatment after burns (p<0.05 Early-Bortezomib vs. vehicle and Late-Bortezomib).
Conclusions
Proteasome inhibition delays development of burn-induced hypermetabolism. Although proteasome inhibition early after burn injury reduces the hypermetabolic response, it significantly increases early burn-associated mortality.